What insider share purchase did Tiziana Life Sciences (TLSA) disclose?

Tiziana Life Sciences disclosed that Executive Chairman and Founder Gabriele Cerrone, through Panetta Partners Ltd, bought 15,000 common shares at $1.11 per share. This increased his total holding to 44,772,230 common shares, representing 34.89% of the company’s issued share capital.

Tiziana (NASDAQ: TLSA) chair lifts stake with 15,000-share purchase

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Tiziana Life Sciences Ltd filed a Form 6-K reporting that Executive Chairman and Founder Gabriele Cerrone, via Panetta Partners Ltd, purchased 15,000 common shares at $1.11 per share, increasing his total holding to 44,772,230 shares, or 34.89% of the company’s issued share capital.

The filing also highlights Tiziana’s lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody in development for non-active secondary progressive multiple sclerosis. Fourteen patients have been treated in an expanded access program, and a Phase 2a randomized, double-blind, placebo-controlled trial is in progress.

Key Figures

Insider purchase size: 15,000 shares Purchase price: $1.11 per share Total holding: 44,772,230 shares +3 more

6 metrics

Insider purchase size 15,000 shares Common shares bought by Executive Chairman at $1.11

Purchase price $1.11 per share Price paid by Executive Chairman for 15,000 shares

Total holding 44,772,230 shares Executive Chairman’s total common share holding after purchase

Ownership percentage 34.89% of issued share capital Executive Chairman’s stake after purchase

Expanded Access patients 14 patients Non-active secondary progressive multiple sclerosis patients dosed with intranasal foralumab

Clinical trial phase Phase 2a Randomized, double-blind, placebo-controlled trial of intranasal foralumab

Key Terms

Expanded Access (EA) Program, Phase 2a, randomized, double-blind, placebo-controlled, monoclonal antibody, +1 more

5 terms

Expanded Access (EA) Program medical

"14 patients with Non-Active Secondary Progressive Multiple Sclerosis ... have been dosed in an open-label intermediate sized Expanded Access (EA) Program"

Phase 2a medical

"intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial"

Phase 2a is an early stage in testing a new medical treatment or drug, where the main goal is to assess its safety and find the right dosage. For investors, this stage indicates whether the treatment shows initial promise before moving on to larger, more definitive studies; progress here can influence expectations for future development and potential success.

randomized, double-blind, placebo-controlled medical

"a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial"

A "randomized, double-blind, placebo-controlled" process is a method used to test the effectiveness of a new treatment or intervention. Participants are randomly assigned to different groups, with one receiving the real treatment and the other a fake version, called a placebo. Neither the participants nor the researchers know who is receiving which, which helps ensure unbiased results. For investors, this rigorous approach increases confidence that the findings are accurate and not influenced by guesswork or bias.

monoclonal antibody medical

"Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate"

A monoclonal antibody is a laboratory-made protein designed to recognize and attach to a specific target in the body, such as a disease-causing substance or cell. It functions like a highly precise lock-and-key tool, helping to treat or detect illnesses. For investors, companies developing monoclonal antibodies can represent promising opportunities in the healthcare sector, especially as these treatments often address unmet medical needs.

immunomodulation therapies medical

"a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate"

Treatments that change how the immune system behaves to prevent or fight disease, either by calming an overactive response or boosting a weak one — like adjusting a thermostat to keep temperature in a safe range. They matter to investors because they can create big market opportunities if proven effective, but also carry high development, clinical trial and regulatory risks that can strongly affect a company’s future value.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 6-K: How Foreign Companies Report to the SEC →

06/15/2026 - 07:00 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

June 2026

Commission File Number: 001-38723

Tiziana Life Sciences LTD

(Exact Name of Registrant as Specified in Its Charter)

9^th Floor

107 Cheapside

London

EC2V 6DN

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

On June 15, 2026, Tiziana Life Sciences LTD (the “Company”) issued this 6K announcing, that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 15,000 common shares at $1.11 per share, bringing his total holding to 44,772,230 common shares, which is 34.89% of issued share capital.

The Announcement is furnished herewith as Exhibit 99.1 to this Report on Form 6-K. The information in the attached Exhibits 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	TIZIANA LIFE SCIENCES LTD

Date: June 15, 2026	By:	/s/ Keeren Shah
		Name:	Keeren Shah
		Title:	Chief Financial Officer

EXHIBIT INDEX

Exhibit No.		Description
99.1		Tiziana Life Sciences LTD Press Release, dated June 15, 2026

Exhibit 99.1

Tiziana Life Sciences Announces Purchase of Shares by Executive Chairman

BOSTON, MA, June 15, 2026 – Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announces that its Executive Chairman and Founder, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 15,000 common shares at $1.11 per share, bringing his total holding to 44,772,230 common shares, which is 34.89% of issued share capital.

About Foralumab

Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.^[1],[2]

About Tiziana Life Sciences

Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative intranasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.

For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.

For further inquiries:

Tiziana Life Sciences Ltd

Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com

^[1]

https://www.pnas.org/doi/10.1073/pnas.2220272120

^[2]

https://www.pnas.org/doi/10.1073/pnas.2309221120

Source: View Original Filing on SEC EDGAR

FAQ

How large is Gabriele Cerrone’s ownership stake in Tiziana Life Sciences (TLSA)?

After the reported purchase, Gabriele Cerrone holds 44,772,230 common shares of Tiziana Life Sciences. This position equals 34.89% of the company’s issued share capital, making him a substantial shareholder through his beneficial interest in Panetta Partners Ltd.

What is Tiziana Life Sciences’ lead drug candidate for multiple sclerosis?

Tiziana Life Sciences’ lead candidate is intranasal foralumab, a fully human anti-CD3 monoclonal antibody. It is being developed as an immunomodulation therapy and is currently studied in non-active secondary progressive multiple sclerosis using intranasal delivery to stimulate T regulatory cells.

What clinical experience exists for intranasal foralumab in multiple sclerosis?

Fourteen patients with non-active secondary progressive multiple sclerosis have received intranasal foralumab in an open-label, intermediate sized Expanded Access Program. The company reports either improvement or stability of disease within six months for all treated patients in this program.

What clinical trial is testing intranasal foralumab for Tiziana Life Sciences (TLSA)?

Intranasal foralumab is in a Phase 2a randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial for non-active secondary progressive multiple sclerosis. This study is designed to further evaluate safety and clinical response for the company’s lead immunomodulation therapy candidate.

How does Tiziana Life Sciences describe its drug delivery approach?

Tiziana Life Sciences describes using transformational drug delivery technologies, including an innovative intranasal approach to immunotherapy. The company states this route may improve efficacy, safety, and tolerability compared to intravenous delivery, supporting a broader pipeline of immunomodulatory therapies.

Filing Exhibits & Attachments

1 document

Press Releases

EX-99.1 TIZIANA LIFE SCIENCES LTD PRESS RELEASE, DATED JUNE 15, 2026 7.5 KB